Lornoxicam - NSAIDs Agents- (FDC- List )-(May 2007)
Drug Name:Lornoxicam - NSAIDs Agents- (FDC- List )-(May 2007)
List Of Brands:
Indication Type Description:
Drug Interaction
Indication
Adverse Reaction
Contra-Indications
Dosages/ Overdosage Etc
Pharmacology/ Pharmacokinetics
Interaction with Food
Pregnancy and lactation
Drug Interaction:
Antacids, anticoagulants, cimetidine, ranitidine, digoxin, arsenide,
Sulphonlureas such as glibencamide,
Indomethicin, other NSAIDs,
Lithium, tripotassium, dicitro bismuthate
Warfarin,
ACE inhibitors, methotrexate,cyclosporine,
Phenytoin, amiodarone, miconazole, rifampicin
Indication:
Adverse Reaction:
Headache,GI disturbances such diarrhea, constipation, nausea,
Vomiting or abdominal pain, flatulence
Dysphagia, dry mouth, stomatitis
GORD, oesophagitis, rectal bleeding,
Ecchymoses, debility depression,
Visual disturbances, dyspepsia
Palpitations, dizziness, leg cramps,
Tinnitus, anaemia, altered taste
Oedema, alopecia, weight changes,
Itching, irritations, redness and rash
Inctreased sweating,
Ulceration or bleeding of the stomach or intestines
Thrombocytopenia. increase in liver enzyme
Contra-Indications:
Active peptic ulcer
Allergy to aspirin or other medicines in this class.
Patients under 18 years years
History of bronchospasm or urticaria orrhinitis or angioedema following admin. of asoirin or NSAIDs
Severely impaired kidney function, cardiac failure
Pregnancy
Lactation
Dosages/ Overdosage Etc:
Indication
Acute pain and osteoarthiritis
Dosage-
Pain relief- adult- 8 -16mg daily max 24mg daily
Osteoporosis- adult - 12mg daily in 2 -3 divided doses up to 16mg daily if needed
Parentral - pain relief - adult - 8mg once or bid by im /iv inj max - 24mg daily
Pharmacology/ Pharmacokinetics:
Pharmacodynamics
Analgesic and anti-inflammatory activity of Lornoxicam is due to its inhibitory action on postagladin synthesis via inhibition of cyclo-oxygenase COX activity. Unlike some NSAIDs however, lomoxicam does not inhibit 5- lipoxy-genase ativity and thus does not inhibit leukotriene synthesis or shunt arachionic acid to the 5- lipogenase pathway.
Pharmacokinetics-
Lornoxicam is rapidly and completely absorbed after oral administration reaching peak plasma concentrations of 270ug/L within 2.5 hours after a 4mg dose. The absorption of Lornoxcam is delayed and marginally reduced 20% in the presence of food.
The bioavailability is essentially 100%. It has an elimination half life of 4 hours, independent of dose Metabolised completely and approximately 1/3 rd is eliminated via the kidneys and 2/3ed via the liver, Its pharmacokinetics is similar in elderly and young subjects
Interaction with Food:
The absorption of Lornoxcam is delayed and marginally reduced 20% in the presence of food.
Pregnancy and lactation:
Contraindicated for use during pregnancy and lactation
Observe caution if required to be administered